Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.06 USD

806.06
3,726,192

-0.08 (-0.01%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

Sweta Killa headshot

Healthcare ETFs in Focus as Q3 Earnings Unfold

The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.

Stock Market News for Oct 27, 2021

U.S. stocks continued their winning streak on Tuesday, with the Dow and the S&P 500 closing at record highs for the second straight day as investors digested a slew of earnings reports from some of biggest American corporations.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.

Eli Lilly (LLY) Q3 Earnings Miss, COVID Drugs Drive Sales

Eli Lilly (LLY) reports mixed third-quarter results and raises its 2021 sales forecast.

Mark Vickery headshot

Home Prices Stay "Lofty;" UPS Beats, Lilly Mixed

The Case-Shiller Home Price Index for August came in at +19.8%, right in-line with what analysts were looking for.

Q3 Earnings Season in Full Swing

Q3 Earnings Season in Full Swing

Eli Lilly (LLY) Misses Q3 Earnings Estimates

Lilly (LLY) delivered earnings and revenue surprises of -2.02% and 1.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.

Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $243.75 in the latest trading session, marking a +1.07% move from the prior day.

Should You Buy Eli Lilly and Company (LLY) Ahead of Earnings?

Eli Lilly and Company (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Teladoc Health's (TDOC) Earnings in Q3?

Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.

Radius (RDUS) Up On Positive Data From Breast Cancer Study

Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.

Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

PFE vs. LLY: Which Stock Is the Better Value Option?

Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib

The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed at $237.88 in the latest trading session, marking a +0.5% move from the prior day.

Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?

Smart Beta ETF report for FLQL

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

Style Box ETF report for FLQL